Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML

Br J Haematol. 2023 Mar;200(5):676-677. doi: 10.1111/bjh.18622. Epub 2022 Dec 21.

Authors

Andromachi Scaradavou¹, Jaap Jan Boelens¹

Affiliation

¹ Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

PMID: 36544239
DOI: 10.1111/bjh.18622

No abstract available

Publication types

Letter
Comment

MeSH terms

Cord Blood Stem Cell Transplantation*
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / drug therapy
Myeloablative Agonists / therapeutic use
Neoplasm Recurrence, Local
Probability
Retrospective Studies
Transplantation Conditioning

Substances

Myeloablative Agonists